Alpine Immune Sciences (Alpine Immune Sciences) EBIT : $-31.98 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Alpine Immune Sciences EBIT?

Alpine Immune Sciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $6.06 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-31.98 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Alpine Immune Sciences's annualized ROC % for the quarter that ended in Dec. 2023 was 7.93%. Alpine Immune Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 266.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Alpine Immune Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -0.82%.

Alpine Immune Sciences EBIT Historical Data

The historical data trend for Alpine Immune Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Immune Sciences EBIT Chart

Alpine Immune Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-41.51

-27.17

-49.60

-54.96

-31.98

Alpine Immune Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-18.23	-13.20	-13.13	-11.72	6.06

Competitive Comparison of Alpine Immune Sciences's EBIT

For the Biotechnology subindustry, Alpine Immune Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpine Immune Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alpine Immune Sciences's EV-to-EBIT falls into.

Alpine Immune Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.98 Mil.

Alpine Immune Sciences (NAS:ALPN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Alpine Immune Sciences's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	6.188 * ( 1 - 1.7% )	/	( (78.357	+	74.988)	/ 2 )
=	6.082804	/	76.6725
=	7.93 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	240.547	-	16.593	-	( 193.453	-	max(0, 51.818	-	197.415	+	193.453	))
=	78.357

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	379.852	-	16.81	-	( 327.412	-	max(0, 41.98	-	330.034	+	327.412	))
=	74.988

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Alpine Immune Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	24.252	/	( ( (9.23 + max(-47.645, 0))	+	(8.994 + max(-39.028, 0)) )	/	2 )
=	24.252	/	( ( 9.23	+	8.994 )	/	2 )
=	24.252	/	9.112
=	266.15 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.219	+	0	+	3.084)	-	(16.593	+	30.092	+	4.263)
=	-47.645

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.167	+	0	+	1.873)	-	(16.81	+	16.288	+	7.97)
=	-39.028

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Alpine Immune Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-31.983	/	3915.087
	=	-0.82 %

Alpine Immune Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpine Immune Sciences (Alpine Immune Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (NAS:ALPN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

34LA:Germany

Address

188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102

Website

https://www.alpineimmunesciences.com

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Executives

Mitchell Gold	director, officer: Executive Chairman and CEO	ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James Paul Rickey	officer: Senior VP and CFO	ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102
Xiangmin Cui	director, 10 percent owner	NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000
Wolfgang Dummer	officer: Chief Medical Officer	5491 OPTICAL CT., SAN JOSE CA 95138
Remy Durand	officer: Chief Business Officer	C/O ALPINE IMMUNE SCIENCES, INC., 185 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98012
Jorn Drappa	director	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878
Andrew Seth Sandler	officer: Chief Medical Officer	1301 2ND AVE, SEATTLE WA 98101
Frazier Life Sciences Viii, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert E Conway	director	C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
Christopher Peetz	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Decheng Capital China Life Sciences Usd Fund Iii, L.p.	10 percent owner	UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
Alpine Immunosciences, L.p.	10 percent owner	600 STEWART STREET, SUITE 1503, SEATTLE WA 98101
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022